These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 35751458)

  • 1. Risk factors of short-term, intermediate-term, and long-term cardiac events in patients hospitalized for HFmrEF.
    Zhu Y; Peng X; Wu M; Huang H; Li N; Chen Y; Xiao S; Zhang H; Zhou Y; Chen S; Liu Z; Yi L; Peng Y; Fan J; Zeng J
    ESC Heart Fail; 2022 Oct; 9(5):3124-3138. PubMed ID: 35751458
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Growth differentiation factor 15 as mortality predictor in heart failure patients with non-reduced ejection fraction.
    Mendez Fernandez AB; Ferrero-Gregori A; Garcia-Osuna A; Mirabet-Perez S; Pirla-Buxo MJ; Cinca-Cuscullola J; Ordonez-Llanos J; Roig Minguell E
    ESC Heart Fail; 2020 Oct; 7(5):2223-2229. PubMed ID: 32589369
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Associations With and Prognostic and Discriminatory Role of N-Terminal Pro-B-Type Natriuretic Peptide in Heart Failure With Preserved Versus Mid-range Versus Reduced Ejection Fraction.
    Savarese G; Orsini N; Hage C; Dahlström U; Vedin O; Rosano GMC; Lund LH
    J Card Fail; 2018 Jun; 24(6):365-374. PubMed ID: 29597053
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Utilizing NT-proBNP for Eligibility and Enrichment in Trials in HFpEF, HFmrEF, and HFrEF.
    Savarese G; Orsini N; Hage C; Vedin O; Cosentino F; Rosano GMC; Dahlström U; Lund LH
    JACC Heart Fail; 2018 Mar; 6(3):246-256. PubMed ID: 29428439
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reductions in N-Terminal Pro-Brain Natriuretic Peptide Levels Are Associated With Lower Mortality and Heart Failure Hospitalization Rates in Patients With Heart Failure With Mid-Range and Preserved Ejection Fraction.
    Savarese G; Hage C; Orsini N; Dahlström U; Perrone-Filardi P; Rosano GM; Lund LH
    Circ Heart Fail; 2016 Nov; 9(11):. PubMed ID: 28029640
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recurrent hospitalizations are associated with increased mortality across the ejection fraction range in heart failure.
    Huusko J; Tuominen S; Studer R; Corda S; Proudfoot C; Lassenius M; Ukkonen H
    ESC Heart Fail; 2020 Oct; 7(5):2406-2417. PubMed ID: 32667143
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Predictive value of N-terminal B-type natriuretic peptide on outcome of elderly hospitalized non-heart failure patients].
    Li YY; Liang YD; Yao SM; Zheng PP; Zeng XZ; Cui LL; Guo D; Wang H; Yang JF
    Zhonghua Xin Xue Guan Bing Za Zhi; 2020 Aug; 48(8):661-668. PubMed ID: 32847322
    [No Abstract]   [Full Text] [Related]  

  • 8. [Contemporary epidemiology and treatment of hospitalized heart failure patients in real clinical practice in China].
    Wang H; Li YY; Chai K; Zhang W; Li XL; Dong YG; Zhou JM; Huo Y; Yang JF
    Zhonghua Xin Xue Guan Bing Za Zhi; 2019 Nov; 47(11):865-874. PubMed ID: 31744275
    [No Abstract]   [Full Text] [Related]  

  • 9. Clinical characteristics of hospitalized heart failure patients with preserved, mid-range, and reduced ejection fractions in Japan.
    Shiga T; Suzuki A; Haruta S; Mori F; Ota Y; Yagi M; Oka T; Tanaka H; Murasaki S; Yamauchi T; Katoh J; Hattori H; Kikuchi N; Watanabe E; Yamada Y; Haruki S; Kogure T; Suzuki T; Uetsuka Y; Hagiwara N;
    ESC Heart Fail; 2019 Jun; 6(3):475-486. PubMed ID: 30829002
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of N-terminal pro-brain natriuretic peptide with contrast-induced acute kidney injury and long-term mortality in patients with heart failure and mid-range ejection fraction: An observation study.
    Wang K; Li HL; Chen LL; Bei WJ; Lin KY; Smyth B; Chen SQ; Guo XS; Guo W; Liu YH; Chen PY; Chen JY; Chen KH; Liu Y; Tan N
    Medicine (Baltimore); 2017 Mar; 96(10):e6259. PubMed ID: 28272231
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bio-profiling and bio-prognostication of chronic heart failure with mid-range ejection fraction.
    Moliner P; Lupón J; Barallat J; de Antonio M; Domingo M; Núñez J; Zamora E; Galán A; Santesmases J; Pastor C; Bayes-Genis A
    Int J Cardiol; 2018 Apr; 257():188-192. PubMed ID: 29415801
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of predictive value of NT-proBNP, sST2 and MMPs in heart failure patients with different ejection fractions.
    Pan W; Yang D; Yu P; Yu H
    BMC Cardiovasc Disord; 2020 Apr; 20(1):208. PubMed ID: 32354356
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of RDW alone and in combination with NT-proBNP in patients with heart failure.
    Liang L; Huang L; Zhao X; Zhao L; Tian P; Huang B; Feng J; Zhang J; Zhang Y
    Clin Cardiol; 2022 Jul; 45(7):802-813. PubMed ID: 35621296
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Soluble Suppression of Tumorogenicity 2 Increases Opportunities for Risk Stratification After Acute Heart Failure Decompensation].
    Skvortsov AA; Protasov VN; Narusov OY; Koshkina DE; Nasonova SN; Masenko VP; Tereschenko SN
    Kardiologiia; 2017 Jan; (1):48-58. PubMed ID: 28290833
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heart Failure With Midrange Ejection Fraction in Patients Admitted for Acute Decompensation: A Report from the Japanese Multicenter Registry.
    Takei M; Kohsaka S; Shiraishi Y; Goda A; Nagatomo Y; Mizuno A; Suzino Y; Kohno T; Fukuda K; Yoshikawa T
    J Card Fail; 2019 Aug; 25(8):666-673. PubMed ID: 31129270
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of NT-proBNP and high sensitivity C-reactive protein for predicting cardiovascular risk in patients with arthritis taking longterm nonsteroidal antiinflammatory drugs.
    Ruff CT; Morrow DA; Jarolim P; Ren F; Contant CF; Kaur A; Curtis SP; Laine L; Cannon CP; Brune K
    J Rheumatol; 2011 Jun; 38(6):1071-8. PubMed ID: 21459935
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Natriuretic peptide plasma concentrations and risk of cardiovascular versus non-cardiovascular events in heart failure with reduced ejection fraction: Insights from the PARADIGM-HF and ATMOSPHERE trials.
    Khan MS; Kristensen SL; Vaduganathan M; Kober L; Abraham WT; Desai AS; Solomon SD; Swedberg K; Dickstein K; Zile MR; Packer M; McMurray JJ; Butler J
    Am Heart J; 2021 Jul; 237():45-53. PubMed ID: 33621540
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High serum fibroblast growth factor 21 levels were related to the prognosis and ventricular remodeling of heart failure patients with mildly reduced and reduced ejection fraction.
    Fan L; Gu L; Yao Y; Ma G
    Perfusion; 2024 Mar; 39(2):285-293. PubMed ID: 36321746
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Growth differentiation factor 15 in heart failure with preserved vs. reduced ejection fraction.
    Chan MM; Santhanakrishnan R; Chong JP; Chen Z; Tai BC; Liew OW; Ng TP; Ling LH; Sim D; Leong KT; Yeo PS; Ong HY; Jaufeerally F; Wong RC; Chai P; Low AF; Richards AM; Lam CS
    Eur J Heart Fail; 2016 Jan; 18(1):81-8. PubMed ID: 26497848
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of sST2 and NT-proBNP at admission in heart failure with preserved, mid-ranged and reduced ejection fraction.
    Huang A; Qi X; Hou W; Qi Y; Zhao N; Liu K
    Acta Cardiol; 2018 Feb; 73(1):41-48. PubMed ID: 28944719
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.